Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Israeli Scientists to Announce Development of Coronavirus Vaccine

By LabMedica International staff writers
Posted on 16 Mar 2020
Over 50 experienced PhD scientists from the Israel Institute for Biological research (IIBR; Ness-Ziona, Israel) are working to produce a vaccine and antibody for the novel coronavirus.

IIBR was established in 1952 as a governmental research institute, founded by a group of scientists from the IDF Science Corps and from academic organizations. More...
Over the years, IIBR has been engaged in R&D in the fields of biology, chemistry, and environmental sciences. Since 1995, it has operated as a government-affiliated unit that research all areas of defense against chemical and biological weapons, including the operation of national laboratories for detection and identification of such threats. IIBR has now been assigned by the Israeli Prime Minister Mr. Benjamin Netanyahu to produce a vaccine and antibody for the novel coronavirus.

According to reports, scientists at IIBR have had a significant breakthrough in understanding the biological mechanism and qualities of the coronavirus and are expected to announce the completion of the development of a vaccine for COVID-19. However, a number of pre-clinical and clinical trials will have to be conducted for months before the vaccination can be deemed as effective or safe to use. Nevertheless, in view of the global emergency over the coronavirus pandemic, the trials could be accelerated to vaccinate a majority of the people who are at the highest risk of contracting the coronavirus.

Related Links:
The Israel Institute for Biological research (IIBR)


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.